Clinical trials: Nonalcoholic Fatty Liver
Steatohepatitis, Nonalcoholic
Formula Diet Treatment for NASH Patients.
Non-alcoholic steatohepatitis (NASH) - also called fatty liver - is medically a serious problem because the liver tissue becomes fatty and stiff, and inflammatory reactions occur.
- Trial name
- NASH (NCT04707651)
- Testing
- Formula diet
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- West German Center of Diabetes and Health
Non-Alcoholic Fatty Liver Disease
Silymarin in NAFLD
This study evaluates the influence of Silymarin in reducing laboratory, ultrasonographic (Fibroscan) and metabolic components of NAFLD. Half of the patients will receive Silymarin (Verum) while the other half will receive placebo
- Trial name
- SINF (NCT02973295)
- Testing
- Silymarin
- Where
- Croatia
- Sponsor
- University Hospital Rijeka
NAFLD, Fatty Liver
A Nutrigenetic Intervention in MASLD
The study is designed as a 12-week randomized controlled dietary intervention in individuals who had been diagnosed with NAFLD in the last 6 months and whose body mass index is above 25 at the time of participation in the…
- Trial name
- NCT06220695
- Testing
- Dietary intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Maastricht University
Nonalcoholic Steatohepatitis
Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis
The purpose of this study is to evaluate the effects of solithromycin on hepatic histology and biomarkers in patients with nonalcoholic steatohepatitis.
- Trial name
- NCT02510599
- Testing
- solithromycin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Melinta Therapeutics, Inc.
Non-alcoholic Fatty Liver Disease (NAFLD), Obesity
"Hepafast" in Non-alcoholic Fatty Liver Disease (NAFLD)
The purpose of this study is to investigate whether a weight reduction with "Hepafast" in combination with raw food and vegetables for two weeks followed by a meal substitution with "Hepafast" and a calorie restriction in…
- Trial name
- NCT02491229
- Testing
- Hepafast, LOGI diet
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Hohenheim
Non Alcoholic Fatty Liver Disease
The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease
The Objective of This Study is Evaluating the Effect of oral β- glucan Supplement on Anthropometric Measurements, Appetite, Insulin Resistance, Liver echogenicity and Enzymes in Non Alcoholic Fatty Liver Patients Treating with…
- Trial name
- NCT02178839
- Testing
- β- glucan, Maltodextrin
- Where
- Iran
- Volunteers
- 48 people
- Sponsor
- Urmia University of Medical Sciences
Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Non-alcoholic fatty liver disease (NAFLD) treatment drug HEC96719 in Healthy Male and Female Subjects
- Trial name
- NCT04422496
- Testing
- HEC96719
- Where
- Australia
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
NAFLD
NASH AMPK Exercise Dosing (AMPED) Trial
There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH.
- Trial name
- AMPED (NCT04987879)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Metabolic Syndrome, Non-alcoholic Fatty Liver Disease
Effect of Dietary Macronutrient Composition
The purpose of this study is to understand why Hispanics who are overweight have a higher incidence of fatty liver disease.
- Conditions
- Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01371396
- Testing
- Low-fat diet, Low-carbohydrate diet
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
NAFLD, Diet Habit
Exploring the Mechanism of Dietary Pattern Improving MAFLD
investigators plan to observe the changes of biochemical indicators, body composition, gut microbiota, metabolomics in patients at different periods through balanced diet and Low-carbohydrate diet, so as to determine the…
- Trial name
- NCT05960396
- Testing
- Diet intervention
- Volunteers
- 80 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-Alcoholic Fatty Liver Disease
Effect of Omega-3 PUFA Supplementation in NAFLD Patients
The purpose of this study is to determine whether dietary supplementation with omega-3 polyunsaturated fatty acids will decrease the amount of fat in liver.
- Trial name
- NCT00230113
- Testing
- Fish oil, Safflower oil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
Obesity and type 2 Diabetes Mellitus prevalence has doubled in the last 30 years and nearly one fifth of UAE population has Type 2 Diabetes while more than quarter has obesity.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Type 2 Diabetes, Liver Fat
- Trial name
- NCT05751720
- Testing
- GIP/GLP-1a
- Where
- United Arab Emirates
- Volunteers
- 30 people
- Sponsor
- Dr Adnan Agha
Non-Alcoholic Fatty Liver Disease, Type2 Diabetes
Characteristics of NAFLD Among Type 2 Diabetes Patients
Type 2 diabetes patients have a high risk of developing NAFLD. This was confirmed during previous research, a high prevalence of NAFLD among type 2 diabetes mellitus patients was found.
- Trial name
- NCT04999124
- Testing
- Screening and studying characteristics
- Where
- Belgium
- Volunteers
- 1,762 people
- Sponsor
- Ziekenhuis Oost-Limburg
Non-Alcoholic Fatty Liver Disease
Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production
All subjects will be evaluated by the Research Nurse at the Clinical Translational Research Center (CTRC) Outpatient Clinic to obtain informed consent, a brief medical history, weight, body mass index, waist/hip circumference and…
- Trial name
- NCT01262326
- Testing
- Calorie and Carbohydrate Restriction
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Non-Alcoholic Fatty Liver Disease
Ultrasound Liver Fat Quantification on Pediatric Patients
This prospective study aims to recruit pediatric patients with confirmed or suspected non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatosis hepatitis (NASH) and who are eligible for standard ultrasound and MRI…
- Trial name
- NCT06095479
- Testing
- 2D ultrasound scan and MRI examination
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Philips (China) Investment CO., LTD
NAFLD - Nonalcoholic Fatty Liver Disease, NASH - Nonalcoholic Steatohepatitis
Effects of Exercise on VLDL-TG Metabolism
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH) and cirrhosis.
- Trial name
- NCT03678727
- Where
- Denmark
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Non-Alcoholic Fatty Liver Disease
Quality of Life in Non-alcoholic Fatty Liver Disease (QOLNAFLD)
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent disorder which is directly linked to lifestyle patterns and is associated with poor quality of life, increased fatigue and psychological distress.
- Trial name
- QOLNAFLD (NCT03613480)
- Testing
- Motivational Interviewing
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University Hospital of Patras
Healthy, NAFLD
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
The primary objective of this study is to evaluate the effect of itraconazole, a strong inhibitor)of cytochrome P4503A , and phenytoin a strong inducer of cytochrome P450 3A, CYP3A4, CYP1A2 and CYP2C19 on the pharmacokinetics of…
- Trial name
- NCT04845646
- Testing
- ASC41, Itraconazole, Phenytoin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Acute Pancreatitis, Nonalcoholic Fatty Liver Disease
Association Between Nonalcoholic Fatty Liver Disease and Acute Pancreatitis
The early evaluation of AP severity are vital. Previous studies have shown non-alcoholic fatty liver disease (NAFLD) is associated with severity of acute pancreatitis (AP).
- Trial name
- NCT03566173
- Where
- China
- Volunteers
- 1,662 people
- Sponsor
- Ningbo No. 1 Hospital
Fatty Liver Disease, Fatty Liver
Impact of Time-restricted Feeding in NAFLD
This is a randomised controlled study of patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Patients will be trained according to the 10 rules of a healthy nutrition according to the German Association for Nutrition (DGE).
- Conditions
- Fatty Liver Disease, Fatty Liver, Fatty Liver, Nonalcoholic
- Trial name
- NAFLD-TRF (NCT05220956)
- Testing
- Intermittent fasting, DGE diet
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Johannes Gutenberg University Mainz
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.